Page contents Key factsDecisionRelated medicine informationKey facts Invented name Ilaris Active Substance Canakinumab Therapeutic area Oncology Decision number P/0029/2020 PIP number EMEA-000060-PIP08-19 Pharmaceutical form(s) Powder for solution for injectionSolution for injection Condition(s) / indication(s) Treatment of lung carcinoma Route(s) of administration Subcutaneous use Contact for public enquiries Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 29/01/2020DecisionP/0029/2020: EMA decision of 29 January 2020 on the granting of a product specific waiver for canakinumab (Ilaris), (EMEA-000060-PIP08-19)AdoptedReference Number: EMA/27127/2020 English (EN) (201.79 KB - PDF)First published: 04/06/2020ViewRelated medicine informationIlarisShare this page